In the latest trading session,, 0.92 million Legend Biotech Corp ADR (NASDAQ:LEGN) shares changed hands as the company’s beta touched 0.14. With the company’s most recent per share price at $37.59 changing hands around $2.81 or 8.09% at last look, the market valuation stands at $6.92B. LEGN’s current price is a discount, trading about -61.93% off its 52-week high of $60.87. The share price had its 52-week low at $27.34, which suggests the last value was 27.27% up since then. When we look at Legend Biotech Corp ADR’s average trading volume, we note the 10-day average is 2.27 million shares, with the 3-month average coming to 1.62 million.
Analysts gave the Legend Biotech Corp ADR (LEGN) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.17. If we narrow down to specifics, the data shows that 0 out of 11 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended LEGN as a Hold, 11 felt it is a Buy and 0 rated the stock as Underweight.
Legend Biotech Corp ADR (NASDAQ:LEGN) trade information
Instantly LEGN is in green as seen in intraday trades today. With action 32.23%, the performance over the past five days has been green. The company’s shares are showing year-to-date upside of 15.53%, with the 5-day performance at 32.23% in the green. However, in the 30-day time frame, Legend Biotech Corp ADR (NASDAQ:LEGN) is 18.29% up. Looking at the short shares, we see there were 7.58 million shares sold at short interest cover period of 4.32 days.
The consensus price target for the stock as assigned by Wall Street analysts is 75, meaning bulls need an upside of 49.88% from its recent market value. According to analyst projections, LEGN’s forecast low is 75 with 75 as the target high. To hit the forecast high, the stock’s price needs a -99.52% plunge from its current level, while the stock would need to soar -99.52% for it to hit the projected low.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 0.79%. The 2025 estimates are for Legend Biotech Corp ADR earnings to increase by 12.66%.
LEGN Dividends
Legend Biotech Corp ADR is expected to release its next quarterly earnings report on 2025-May-12.
Legend Biotech Corp ADR (NASDAQ:LEGN)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 1.33% of Legend Biotech Corp ADR shares while 47.78% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 48.42%. There are 47.78% institutions holding the Legend Biotech Corp ADR stock share, with FMR LLC the top institutional holder. As of 2024-06-30, the company held 9.6503% of the shares, roughly 17.62 million LEGN shares worth $780.46 million.
PRICE T ROWE ASSOCIATES INC /MD/ holds the second largest percentage of outstanding shares, with 6.292% or 11.49 million shares worth $508.86 million as of 2024-06-30.
Among Mutual Funds, the top two as of Jan 31, 2025 were AIM Investment Fd.s -Invesco Developing Markets Fd. and Fidelity Select Portfolios-Health Care Portfolio . With 2.96 shares estimated at $112.06 million under it, the former controlled 1.61% of total outstanding shares. On the other hand, Fidelity Select Portfolios-Health Care Portfolio held about 1.52% of the shares, roughly 2.8 shares worth around $105.85 million.
